Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of the IN006 bivalent mRNA RSV vaccine in healthy adults aged 60 years and older
CTR20252903Phase 2Active
- Sponsor
- 深圳深信生物科技有限公司
- Start
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of IN006 in respiratory syncytial virus disease (RSV), sponsored by 深圳深信生物科技有限公司. Started Aug 2025; status: active.
02
Drugs
IN006
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20252903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252903.